Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon BI, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz-Price LS, Carmeli Y, Kaye KS. Collins VL, et al. Among authors: carmeli y. Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7. doi: 10.1128/AAC.05913-11. Epub 2012 Jan 30. Antimicrob Agents Chemother. 2012. PMID: 22290982 Free PMC article.
Combination therapy for carbapenem-resistant Gram-negative bacteria.
Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. Paul M, et al. Among authors: carmeli y. J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168. Epub 2014 May 28. J Antimicrob Chemother. 2014. PMID: 24872346 Review.
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ, Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sánchez-García M, Viale P, Wolff M, Carmeli Y. Temkin E, et al. Among authors: carmeli y. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01964-16. doi: 10.1128/AAC.01964-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27895014 Free PMC article.
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.
Harris PNA, Pezzani MD, Gutiérrez-Gutiérrez B, Viale P, Hsueh PR, Ruiz-Garbajosa P, Venditti M, Tumbarello M, Navarro-Francisco C, Calbo E, Akova M, Giamarellou H, Oliver A, Almirante B, Gasch O, Martínez-Martínez L, Schwaber MJ, Daikos G, Pitout J, Peña C, Hernández-Torres A, Doi Y, Pérez F, Tuon FF, Tacconelli E, Carmeli Y, Bonomo RA, Pascual Á, Paterson DL, Rodríguez-Baño J; ESGBIS/REIPI/INCREMENT Group. Harris PNA, et al. Among authors: carmeli y. Int J Antimicrob Agents. 2017 Nov;50(5):664-672. doi: 10.1016/j.ijantimicag.2017.08.005. Epub 2017 Aug 3. Int J Antimicrob Agents. 2017. PMID: 28782704 Free article.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Tacconelli E, et al. Among authors: carmeli y. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. Lancet Infect Dis. 2018. PMID: 29276051
412 results